XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.22.2

Acquisitions, Research Collaborations and License Agreements (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Jul. 31, 2022 | May 31, 2022 | Apr. 30, 2021 | Jan. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Research and development |  |  |  |  | $ 2,798.0 | $ 4,321.0 | $ 5,374.0 | $ 6,732.0
Pandion Therapeutics |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | 1,700.0
Consideration transferred, asset acquisition |  |  | $ 1,900.0 |  |  |  |  |
Transaction cost, asset acquisition |  |  | 147.0 |  |  |  |  |
Asset Acquisition, Other Assets and Liabilities Recognized, Net |  |  | $ 156.0 |  |  |  |  |
Orion Corporation | Licensing Agreements | Subsequent Event |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Upfront and milestone payments | $ 290.0 |  |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Upfront and milestone payments |  | $ 30.0 |  |  |  |  |  |
Milestone payments to be made to a collaborative partner |  | 30.0 |  |  |  |  |  |
Milestone payment to be made to a collaborative partner |  | 25.0 |  |  |  |  |  |
Research and development payments to be made to a collaborative partner |  | 101.0 |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Subsequent Event |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Upfront and milestone payments | 35.0 |  |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  | 90.0 |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones | Subsequent Event |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement | 82.0 |  |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Regulatory Milestones | Subsequent Event |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement | 334.0 |  |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  | 780.0 |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones | Subsequent Event |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement | $ 485.0 |  |  |  |  |  |  |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | First Commercial Sale Milestones |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  | $ 290.0 |  |  |  |  |  |
Artiva Biotherapeutics, Inc. | Licensing Agreements |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Upfront and milestone payments |  |  |  | $ 30.0 |  |  |  |
Upfront and milestone payments to be made |  |  |  | $ 15.0 |  |  |  |
Artiva Biotherapeutics, Inc. | Licensing Agreements | Minimum |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Royalty rate |  |  |  | 7.00% |  |  |  |
Artiva Biotherapeutics, Inc. | Licensing Agreements | Maximum |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Royalty rate |  |  |  | 14.00% |  |  |  |
Artiva Biotherapeutics, Inc. | Licensing Agreements | Development Milestones |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  |  |  | $ 217.5 |  |  |  |
Artiva Biotherapeutics, Inc. | Licensing Agreements | Regulatory Milestones |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  |  |  | 570.0 |  |  |  |
Artiva Biotherapeutics, Inc. | Licensing Agreements | Sales-Based Milestones |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Contingent milestone payments collaborative arrangement |  |  |  | $ 1,050.0 |  |  |  |
COVID-19 |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |
Charges related to program discontinuation |  |  |  |  |  | $ 37.0 |  | $ 207.0

X
- Definition Asset Acquisition, Other Assets and Liabilities Recognized, Net + References No definition available. + Details
Name: | mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Charges related to program discontinuation + References No definition available. + Details
Name: | mrk_ChargesRelatedToProgramDiscontinuation
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. + References No definition available. + Details
Name: | mrk_ContingentPaymentsCollaborativeArrangement
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payment to be Made to a Collaborative Partner + References No definition available. + Details
Name: | mrk_MilestonePaymentToBeMadeToACollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments to be Made to a Collaborative Partner + References No definition available. + Details
Name: | mrk_MilestonePaymentsToBeMadeToACollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Payments to be Made to a Collaborative Partner + References No definition available. + Details
Name: | mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Rate, Percentage + References No definition available. + Details
Name: | mrk_RoyaltyRatePercentage
Namespace Prefix: | mrk_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront and milestone payments made to partner as part of collaborative arrangement. + References No definition available. + Details
Name: | mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and Milestone Payments to be Made to Collaborative Partner + References No definition available. + Details
Name: | mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 55 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 30 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 50 -Section 55 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=mrk_PandionTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_OrionCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mrk_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=mrk_FirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_ArtivaBiotherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |